Evidence map›Paper›PMID 31364976›Full record

ReviewCanadian Urological Association journal = Journal de l'Association des urologues du Canada2019

Management algorithms for prostate-specific antigen progression in prostate cancer: Biochemical recurrence after definitive therapy and progression to non-metastatic castrate-resistant prostate cancer.

Brita Danielson, Fred Saad, Alan So, Scott Morgan, Robert J Hamilton, Shawn Malone, Laura Park-Wyllie, Anousheh Zardan, Bobby Shayegan

Open access · diamondAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Optimizing therapy for high-risk biochemically recurrent non-metastatic prostate cancer Current and emerging strategies.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2025
    Review
  2. Salvage lymph node dissection for prostate-specific membrane antigen (PSMA) positron emission tomography (PET)-identified oligometastatic disease.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2021
    Article
  3. Article
  4. Management algorithms for metastatic prostate cancer.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 3 countries.

Brita DanielsonCross Cancer Institute, University of Alberta, Edmonton, AB, Canada.
Fred SaadCentre Hospitalier de l'Université de Montréal, Université de Montréal, Montreal, QC, Canada.
Alan SoVancouver Prostate Centre, University of British Columbia, BC, Canada.
Scott MorganThe Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada.
Robert J HamiltonPrincess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.
Shawn MaloneThe Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada.
Laura Park-WyllieMedical Affairs, Janssen Inc., Toronto, ON, Canada.
Anousheh ZardanMedical Affairs, Janssen Inc., Toronto, ON, Canada.
Bobby ShayeganJuravinski Cancer Centre, McMaster University, Hamilton, ON, Canada.
Centre Hospitalier de l’Université de Montréal · CAMcMaster University · CAOttawa Hospital · CAUniversity of Alberta · CAUniversity of Ottawa · CAUniversity of Toronto · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionCurrent prostate cancer (PCa) guidelines primarily focus on localized or metastatic PCa. A multidisciplinary genitourinary oncology panel determined that additional guidance focusing on monitoring and management of biochemical recurrence (BCR) following radical therapy and non-metastatic castration-resistant prostate cancer (nmCRPC) was warranted.

methodsThe most up-to-date national and international guidelines, consensus statements, and emerging phase 3 trials were identified and used to inform development of algorithms by a multidisciplinary genitourinary oncology panel outlining optimal monitoring and treatment for patients with non-metastatic PCa.

resultsA total of eight major national and international guidelines/consensus statements published since 2015 and three phase 3 trials were identified. Working group discussions among the multidisciplinary genitourinary oncology panel led to the development of two algorithms: the first addressing management of patients with BCR following radical therapy (post-BCR), and the second addressing management of nmCRPC. The post-BCR algorithm suggests consideration of early salvage treatment in select patients and provides guidance regarding observation vs. intermittent or continuous androgen-deprivation therapy (ADT). The nmCRPC algorithm suggests continued ADT and monitoring for all patients, with consideration of treatment with apalutamide or enzalutamide for patients with high-risk disease (prostate-specific antigen [PSA] doubling time of ≤ 10 months).

conclusionsTwo treatment algorithms have been developed to guide the management of non-metastatic PCa and should be considered in the context of local guidelines and practice patterns.

Identifiers

PMID31364976
PMCPMC6892682
OpenAlexW2911633935

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.